Rybelsus®

Semaglutide

Rybelsus tabletter (semaglutide) er et reseptbelagt legemiddel som brukes hos voksne med type 2 diabetes mellitus for å redusere blodsukkernivået. Rybelsus kan foreskrives når andre diabetesmedisiner har blitt prøvd uten suksess og bør brukes sammen med kosthold og trening. Rybelsus tabletter arbeider for å senke blodsukkernivået (glukose) ved å øke hvor mye insulin som frigjøres og redusere glucagon sekresjon. Denne medisinen kan også bremse gastrisk tømming etter å ha spist.
more
Sending Per pille Pris Besparelse Ordre
90 tablet
Gratis AirMail sending Hot
kr 166.76
kr 15008.20kr 166.76
kr 2000.06
60 tablet
Gratis AirMail sending Hot
kr 177.87
kr 10672.34kr 177.87
kr 666.50
30 tablet
Gratis AirMail sending Hot
kr 188.98
kr 5669.42kr 188.98
Sending Per pille Pris Besparelse Ordre
90 tablet
Gratis AirMail sending Hot
kr 200.11
kr 18009.96kr 200.11
kr 999.47
60 tablet
Gratis AirMail sending Hot
kr 205.67
kr 12339.98kr 205.67
kr 332.97
30 tablet
Gratis AirMail sending Hot
kr 211.22
kr 6336.48kr 211.22
Sending Per pille Pris Besparelse Ordre
90 tablet
Gratis AirMail sending Hot
kr 239.02
kr 21512.00kr 239.02
kr 999.47
60 tablet
Gratis AirMail sending Hot
kr 244.58
kr 14674.68kr 244.58
kr 332.97
30 tablet
Gratis AirMail sending Hot
kr 250.13
kr 7503.82kr 250.13
Rybelsus

Merke(r)

Produsenter

  • Novo Nordisc India Pvt. Ltd

Sykdommer

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.